Lipohypertrophy and Insulin: An Update From the Diabetes Technology Society

Tiffany Tian; Rachel E Aaron; Jingtong Huang; Andrea M Yeung; Jannet Svensson; Sandro Gentile; Angus Forbes; Lutz Heinemann; Jane Jeffrie Seley; David Kerr; David C Klonoff

doi:10.1177/19322968231187661

Lipohypertrophy and Insulin: An Update From the Diabetes Technology Society

Tiffany Tian, Rachel E Aaron, Jingtong Huang, Andrea M Yeung, Jannet Svensson, Sandro Gentile, Angus Forbes, Lutz Heinemann, Jane Jeffrie Seley, David Kerr, David C Klonoff

Steno Diabetes Center Copenhagen

12 Citations (Scopus)

Abstract

Lipohypertrophy is a common skin complication associated with insulin-treated diabetes. The impact of lipohypertrophy as a contributing factor to suboptimal glycemic control, glucose variability, and hypoglycemia is often under-recognized by health care professionals. In a recent Webinar on April 26, 2023, Diabetes Technology Society asked international experts to provide updates on the latest knowledge related to lipohypertrophy for practicing clinicians and educators, researchers, and industries involved in insulin delivery. A recording of the Webinar is freely available on the Diabetes Technology Society Web site (https://www.diabetestechnology.org/).

Original language	English
Journal	Journal of diabetes science and technology
Volume	17
Issue number	6
Pages (from-to)	1711-1721
Number of pages	11
ISSN	1932-2968
DOIs	https://doi.org/10.1177/19322968231187661
Publication status	Published - Nov 2023

Keywords

diabetes
diabetes education
glucose management
insulin
lipohypertrophy
ultrasound
Humans
Diabetes Mellitus, Type 1/drug therapy
Lipodystrophy/chemically induced
Hypoglycemia/complications
Insulin, Regular, Human
Hypoglycemic Agents/adverse effects
Insulin/adverse effects

Access to Document

10.1177/19322968231187661

Cite this

@article{1ce59cda493f40e3883524781db29ea2,

title = "Lipohypertrophy and Insulin: An Update From the Diabetes Technology Society",

abstract = "Lipohypertrophy is a common skin complication associated with insulin-treated diabetes. The impact of lipohypertrophy as a contributing factor to suboptimal glycemic control, glucose variability, and hypoglycemia is often under-recognized by health care professionals. In a recent Webinar on April 26, 2023, Diabetes Technology Society asked international experts to provide updates on the latest knowledge related to lipohypertrophy for practicing clinicians and educators, researchers, and industries involved in insulin delivery. A recording of the Webinar is freely available on the Diabetes Technology Society Web site (https://www.diabetestechnology.org/).",

keywords = "diabetes, diabetes education, glucose management, insulin, lipohypertrophy, ultrasound, Humans, Diabetes Mellitus, Type 1/drug therapy, Lipodystrophy/chemically induced, Hypoglycemia/complications, Insulin, Regular, Human, Hypoglycemic Agents/adverse effects, Insulin/adverse effects",

author = "Tiffany Tian and Aaron, \{Rachel E\} and Jingtong Huang and Yeung, \{Andrea M\} and Jannet Svensson and Sandro Gentile and Angus Forbes and Lutz Heinemann and Seley, \{Jane Jeffrie\} and David Kerr and Klonoff, \{David C\}",

year = "2023",

month = nov,

doi = "10.1177/19322968231187661",

language = "English",

volume = "17",

pages = "1711--1721",

journal = "Journal of diabetes science and technology",

issn = "1932-2968",

publisher = "Diabetes Technology Society",

number = "6",

}

TY - JOUR

T1 - Lipohypertrophy and Insulin

T2 - An Update From the Diabetes Technology Society

AU - Tian, Tiffany

AU - Aaron, Rachel E

AU - Huang, Jingtong

AU - Yeung, Andrea M

AU - Svensson, Jannet

AU - Gentile, Sandro

AU - Forbes, Angus

AU - Heinemann, Lutz

AU - Seley, Jane Jeffrie

AU - Kerr, David

AU - Klonoff, David C

PY - 2023/11

Y1 - 2023/11

N2 - Lipohypertrophy is a common skin complication associated with insulin-treated diabetes. The impact of lipohypertrophy as a contributing factor to suboptimal glycemic control, glucose variability, and hypoglycemia is often under-recognized by health care professionals. In a recent Webinar on April 26, 2023, Diabetes Technology Society asked international experts to provide updates on the latest knowledge related to lipohypertrophy for practicing clinicians and educators, researchers, and industries involved in insulin delivery. A recording of the Webinar is freely available on the Diabetes Technology Society Web site (https://www.diabetestechnology.org/).

AB - Lipohypertrophy is a common skin complication associated with insulin-treated diabetes. The impact of lipohypertrophy as a contributing factor to suboptimal glycemic control, glucose variability, and hypoglycemia is often under-recognized by health care professionals. In a recent Webinar on April 26, 2023, Diabetes Technology Society asked international experts to provide updates on the latest knowledge related to lipohypertrophy for practicing clinicians and educators, researchers, and industries involved in insulin delivery. A recording of the Webinar is freely available on the Diabetes Technology Society Web site (https://www.diabetestechnology.org/).

KW - diabetes

KW - diabetes education

KW - glucose management

KW - insulin

KW - lipohypertrophy

KW - ultrasound

KW - Humans

KW - Diabetes Mellitus, Type 1/drug therapy

KW - Lipodystrophy/chemically induced

KW - Hypoglycemia/complications

KW - Insulin, Regular, Human

KW - Hypoglycemic Agents/adverse effects

KW - Insulin/adverse effects

UR - https://www.scopus.com/pages/publications/85167448293

U2 - 10.1177/19322968231187661

DO - 10.1177/19322968231187661

M3 - Editorial

C2 - 37555266

SN - 1932-2968

VL - 17

SP - 1711

EP - 1721

JO - Journal of diabetes science and technology

JF - Journal of diabetes science and technology

IS - 6

ER -

Lipohypertrophy and Insulin: An Update From the Diabetes Technology Society

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this